BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $962 | -78.3% | 14,126 | -74.0% | 0.01% | -76.7% |
| Q2 2023 | $4,435 | -6.8% | 54,335 | -15.3% | 0.04% | -10.4% |
| Q1 2023 | $4,757 | -9.7% | 64,126 | +0.9% | 0.05% | -12.7% |
| Q4 2022 | $5,267 | -99.9% | 63,552 | +289.5% | 0.06% | +1.9% |
| Q3 2022 | $4,635,000 | +45.2% | 16,316 | +121.3% | 0.05% | +74.2% |
| Q1 2022 | $3,193,000 | +53.0% | 7,374 | +82.8% | 0.03% | +63.2% |
| Q4 2021 | $2,087,000 | +8.1% | 4,035 | +1.3% | 0.02% | +5.6% |
| Q3 2021 | $1,931,000 | -23.5% | 3,985 | -28.9% | 0.02% | -21.7% |
| Q2 2021 | $2,525,000 | +17.9% | 5,608 | 0.0% | 0.02% | +9.5% |
| Q1 2021 | $2,142,000 | +8.7% | 5,608 | -9.7% | 0.02% | +5.0% |
| Q4 2020 | $1,971,000 | -37.0% | 6,208 | -50.9% | 0.02% | -42.9% |
| Q3 2020 | $3,131,000 | -39.9% | 12,640 | -35.9% | 0.04% | -43.5% |
| Q2 2020 | $5,210,000 | -1.5% | 19,730 | -29.3% | 0.06% | -16.2% |
| Q1 2020 | $5,288,000 | -15.4% | 27,888 | -2.1% | 0.07% | +7.2% |
| Q4 2019 | $6,254,000 | +12.2% | 28,488 | 0.0% | 0.07% | +3.0% |
| Q3 2019 | $5,574,000 | +8.0% | 28,488 | +15.1% | 0.07% | +6.3% |
| Q2 2019 | $5,160,000 | +4.6% | 24,751 | -0.4% | 0.06% | +3.3% |
| Q1 2019 | $4,934,000 | +37.2% | 24,851 | 0.0% | 0.06% | +22.0% |
| Q4 2018 | $3,596,000 | -5.7% | 24,851 | +33.0% | 0.05% | +8.7% |
| Q3 2018 | $3,814,000 | +278.7% | 18,687 | +174.5% | 0.05% | +283.3% |
| Q2 2018 | $1,007,000 | -2.0% | 6,808 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $1,028,000 | +9.2% | 6,808 | -6.2% | 0.01% | +9.1% |
| Q4 2017 | $941,000 | +7.2% | 7,260 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $878,000 | +2.9% | 7,260 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $853,000 | +6.8% | 7,260 | -7.6% | 0.01% | +10.0% |
| Q1 2017 | $799,000 | -10.7% | 7,860 | -9.7% | 0.01% | -9.1% |
| Q4 2016 | $895,000 | -10.1% | 8,700 | -4.4% | 0.01% | -15.4% |
| Q3 2016 | $996,000 | +2.7% | 9,100 | +5.8% | 0.01% | 0.0% |
| Q2 2016 | $970,000 | +19.3% | 8,600 | 0.0% | 0.01% | +18.2% |
| Q1 2016 | $813,000 | +5.0% | 8,600 | 0.0% | 0.01% | +10.0% |
| Q4 2015 | $774,000 | +8.7% | 8,600 | +11.7% | 0.01% | +11.1% |
| Q3 2015 | $712,000 | +3.3% | 7,700 | +10.0% | 0.01% | +12.5% |
| Q2 2015 | $689,000 | -1.9% | 7,000 | 0.0% | 0.01% | 0.0% |
| Q1 2015 | $702,000 | +8.5% | 7,000 | 0.0% | 0.01% | +14.3% |
| Q4 2014 | $647,000 | – | 7,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |